| Document |
Document Title |
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/076635A2 |
Described herein, inter alia, are suppressors of site IQ electron leak (SIQELs) and uses thereof.
|
|
WO/2024/049829A3 |
A pharmaceutical composition comprising a compound a binding pocket adjacent the wedge domain of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTPμ) and that ...
|
|
WO/2024/070432A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is used for the formation of an optically anisotropic film that exhibits excellent amine resistance; an optically anisotropic film; an optical f...
|
|
WO/2024/067773A1 |
Provided herein are compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical ...
|
|
WO/2024/073283A1 |
Disclosed herein are amino bicyclic nitrogen heterocyclic ring system compounds which inhibit nuclear receptor-binding SET domain proteins (NSD's), such as 6-amino-9H-purin-9-yl, 8-amino imidazo[1,2-a]pyrazin-3-yl, imidazo[2,1-f][1,2,4]t...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/061658A1 |
The present invention provides compounds of general formula (I): or pharmaceuticaly acceptable salts, solvates or hydrates thereof, wherein RN is independently -H or - Me; RX is independently C1-4 alkyl, optionaly substituted with halo o...
|
|
WO/2024/063670A1 |
The present invention relates to novel compounds of formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, which exhibit the properties of a CDK7 inhibitor, as well as to a pharmaceutical composition containin...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/052353A1 |
The present invention relates to a method for inducing proximity between two biological molecules in a sample, to an assay relying on the induction of proximity between two biological molecules in a sample, and to a proximity inducing sy...
|
|
WO/2024/054766A2 |
The present application discloses a distinct class of mitochondrial uncoupling compounds as well as conventional mitochondrial uncoupling compounds with drastically improved pharmacokinetic properties, pharmaceutical compositions contain...
|
|
WO/2024/049017A1 |
The present invention relates to an organic semiconductor compound with high transmittance in the visible light spectrum and a use thereof.
|
|
WO/2024/043334A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another dru...
|
|
WO/2024/042834A1 |
Provided is a mixed composition for a polymerizable liquid crystal compound that has a low phase transition temperature and is preferably suited to production of a retardation film that has excellent optical characteristics.
|
|
WO/2024/031242A1 |
A method for synthesizing an aryl benzyl thioether compound using photocatalysis. By using the iron (III) complex [HIMXy Me][FeBr 4]([HIMXy Me]=l,3-bis(4-methoxy-2,6-dimethylphenyl)-4,5-dimethylimidaz
olium cation) as a catalyst, fac-Ir(...
|
|
WO/2024/035876A2 |
Disclosed herein are compositions and methods for treating glioblastoma.
|
|
WO/2024/032530A1 |
Provided are an aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, a preparation method and a use thereof. Specifically, provided are a compound of formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutic...
|
|
WO/2024/027706A1 |
Provided herein are heteroaromatic compounds which target Bcl-xL proteins for ubiquitination and proteasomal degradation. Also provided herein are methods for using said compounds for the treatment of diseases.
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/021626A1 |
Disclosed in the present invention are pramipexole xinafoate and a sustained-release pharmaceutical preparation thereof. In the present invention, after pramipexole is prepared into pramipexole xinafoate, the solubility of salts of prami...
|
|
WO/2024/021625A1 |
A crystal form A of pramipexole xinafoate salt ((S)-(-)-2-amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothia
zole bis(1-hydroxynaphthoate) and a preparation method for the crystal form A. The structural formula of the pramipexole xinafoat...
|
|
WO/2024/022546A1 |
The present invention provides 2-arylbenzothiazole derivatives of general formula I, or pharmaceutically acceptable salts thereof with alkali metals, ammonia or amines, or their addition salts with acids, wherein R1 is selected from NHCO...
|
|
WO/2024/019444A1 |
Provided is an organic compound contributing to improving the substantial light efficiency and field of view of an organic electroluminescent device. The organic electroluminescent device according to the present invention comprises: a f...
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2024/010050A1 |
[Problem] The purpose of the present invention is to provide a compound that prevents internal elemental deterioration of an organic EL element, that, in order to significantly improve light-extraction efficiency, does not affect materia...
|
|
WO/2024/008805A1 |
The invention relates to heteroaromatic ketones of formula (I) for radical and cationic polymerization (I), wherein the substituents A, B, C and D can be the same or different and are nitrogen or carbon, while R1 and R2, independently of...
|
|
WO/2024/008166A1 |
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represen...
|
|
WO/2024/003557A1 |
Described herein are compounds of formula I, or a salt or solvate, thereof formula (I). Also described are pharmaceutical compositions and combinations comprising the compounds, and their use in the treatment of conditions mediated by ly...
|
|
WO/2024/003558A1 |
Provided is a compound, or a salt or solvate thereof, according to formula I: as defined herein, and pharmaceutical compositions and combinations comprising said compounds. Also described are said compounds for use in therapy, in particu...
|
|
WO/2024/005578A1 |
The present invention relates to novel indenone derivatives, isomers thereof or pharmaceutically acceptable salts thereof, and uses thereof. The indenone derivatives according to the present invention may be advantageously used for (i) t...
|
|
WO/2024/006402A1 |
The present disclosure relates to compounds comprising histone deacetylase 3 (HDAC3) targeting ligand conjugated to a Degron binding E3 ubiquitin ligase to achieve recruitment of the E3 ubiquitin ligase to HDAC3. Further disclosed compos...
|
|
WO/2023/245777A1 |
The present invention relates to the field of catalysts, and in particular to a heterogeneous catalyst for producing a vulcanization accelerator TBBS by means of an oxygen method, and a preparation method for the heterogeneous catalyst a...
|
|
WO/2023/246836A1 |
The present application relates to the technical field of biological medicines, and in particular relates to a novel five-membered heterocycle substituted styrene derivative, and a preparation method therefor and the use thereof. The sty...
|
|
WO/2023/236920A1 |
This disclosure provides compounds of Formula (1), compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by axonal degeneration.
|
|
WO/2023/238683A1 |
The present invention addresses the problem of providing a novel compound that can be used as a luminescent substrate in a firefly bioluminescence system. The solution for the problem is a heterocyclic compound characterized by being rep...
|
|
WO/2023/238138A1 |
The present invention relates to a motorcycle tyre tread base rubber composition using recovered carbon black and its method thereof. A motorcycle tyre tread base rubber composition includes 100 parts by weight of a rubber; with the tri-...
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/234173A1 |
Provided is a method for detecting an amine compound which makes it possible to detect an amine compound by using an electrochemical measurement. This method for detecting an amine compound includes: contacting a specimen and an isothioc...
|
|
WO/2023/229859A1 |
During the production of Hexahydro-1, 3, 5-trinitro-l, 3, 5-triazine and Octahydro-1,3, 5, 7-tetranitro-l, 3,5, 7-tetrazocine via the Bachmann nitrolysis process, it is necessary to recover the entire mass of acetic acid and restore it t...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/225300A2 |
This disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing sickle cell disease or conditions associated thereto. In certain embodiments, the compounds are 1-(thiazol-2-yl)urea derivatives. In...
|
|
WO/2023/219106A1 |
The present invention addresses the problem of providing a solid derivative of 2-methyl-2-thiazoline that is easy to handle during formulation and is useful as an active pharmaceutical ingredient. The present invention provides: a 1,5-na...
|
|
WO/2023/216992A1 |
Provided are a cyanine-trehalose compound, a method for preparing same, and use thereof. Specifically, the compound is represented by formula I. The cyanine-trehalose compound can be used for detecting Mycobacterium tuberculosis, and fea...
|
|
WO/2023/210772A1 |
A first problem to be addressed by the present invention is to provide a photoelectric conversion element that has excellent quantum efficiency when receiving blue light. A second problem to be addressed by the present invention is to pr...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/211945A1 |
This application is directed to inhibitors of represented by the following structural formula, and methods for their use in modulating MCT in a disease or disorder, such as cancer or neurodegenerative diseases.
|
|
WO/2023/211938A1 |
This application is directed to modulators of MCT represented by the following structural formula (I) and methods for their use, such as to treat cancer or neurodegenerative diseases.
|
|
WO/2023/211942A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable prodrugs, solvates, or salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed he...
|
